Cystatin C Assay Market worth $540 million by 2028

I am healthcareresearch (ps3001626@gmail.com). I hold full responsibility for this content, which includes text, images, links, and files. The website administrator and team cannot be held accountable for this content. If there is anything you need to discuss, you can reach out to me via ps3001626@gmail.com email.

Disclaimer: The domain owner, admin and website staff of New York City US, had no role in the preparation of this post. New York City US, does not accept liability for any loss or damages caused by the use of any links, images, texts, files, or products, nor do we endorse any content posted in this website.

Cystatin C Assay Market in terms of revenue was estimated to be worth $377 million in 2023 and is poised to reach $540 million by 2028, growing at a CAGR of 7.5% from 2023 to 2028 according to a new report by MarketsandMarkets™. The growth of this market is majorly driven by growing number of old age population and rising number of kidney diseases. However, high development costs of cystatin C assay may challenge the growth of this market.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=186075328

Browse in-depth TOC on “Cystatin C Assay Market”

215 – Tables
42 – Figures
271 – Pages

UK in European cystatin C assay market to witness the highest shares during the forecast period.

The European cystatin C assay market is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. UK is projected to occupy the highest share during the forecast period. Market growth is attributed to the rising geriatric population & chronic diseases, increasing number of accredited clinical & hospital laboratories, growing government healthcare expenditure.

Clinical laboratories in End user’ cystatin C assay market to witness the second highest growth rate during the forecast period.

Based on the end user, cystatin C assay market is segmented into hospitals, clinical laboratories, and pharmaceutical & biotechnology companies & CROs & academic research institutes The clinical laboratories registered the second highest CAGR, due to the growing number of clinical tests performed in laboratories and the increasing number of accredited laboratories, and serving as centralized hubs for diagnostic testing, where a wide array of tests, including cystatin C assays which support market growth.

China dominates the Asia Pacific cystatin C assay market.

The APAC cystatin C assay market is segmented into Japan, China, India, and Rest of Apac. In 2022, China accounted for the largest share of the Asian cystatin C assay market. The large share of China can be attributed to the government efforts to increase awareness about the early detection of diseases and regular health check-ups; rising healthcare expenditure; the increasing number of hospitals and clinical diagnostic laboratories in India and China; and strengthening research base for diagnostic procedures across India, China, and Japan, rising cases of CKD.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=186075328

Cystatin C Assay Market Dynamics:

Drivers:

1. Rising prevalence of kidney diseases
2. Growing geriatric population
3. Recent advancements in chemiluminescence immunoassay technologies
4. Growth in biotechnology and biopharmaceutical industries
5. Increasing adoption of POC testing
6. Supportive government policies

Restraints:

1. Stringent requirements for approval of cystatin C assay instruments and consumables
2. High development costs of cystatin C assays

Opportunities:

1. Growth opportunities in emerging economies
2. Importance of companion diagnostics
3. Development of condition-specific biomarkers and tests

Challenge:

1. Dearth of skilled professionals

Key Market Players of Antibody Drug Conjugates Industry:

The significant players in the cystatin C assay are Siemens Healthcare GmbH (Germany), Thermo Fisher Scientific Inc. (US), Abbott (US), Roche Diagnostics Limited. (Switzerland), and Bio-Techne (US), Randox Laboratories Ltd. (UK), DiaSys Diagnostic Systems GmbH (Germany), and Eurolyser Diagnostica GmbH (Austria)

Recent Developments:

• September 2022, Gentian Cystatin C and GCAL assays received IVDR (In-Vitro Diagnostic Regulation) by TüV SÜD.
• March 2021, Roche acquired GenMark Diagnostics at USD 24.05 per share and a total transactional value of USD 1.8 billion. The acquisition strengthened Roche’s Diagnostics portfolio.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=186075328